I went to the Color company's website and browsed around:/www.color.com/product/color-genetic-tests
I think it is quite a useful genetic test in general because it tests for many gene mutations, not just those for prostate cancer. In fact, for prostate cancer, having the BRCA2 gene only slightly increases your risk of prostate cancer, but having the APC mutation dramatically increases the risk of colorectal cancer. Knowing your risk should you have the APC mutation may affect, say, the frequency of colonoscopy. Additionally knowing that I have any mutations at all may be useful information for children or relatives.
For a treated PC patient with persistent or rising PSA, having the BRCA2 or CHK2 mutations may also be a useful test to help determine the aggressiveness of the disease. Particularly, the likelihood of local vs metastatic spread although a full genetic test like PROLARIS would be getter, albeit much more expensive. This may affect the decision to have radiation early in the search for a cure.
For me specifically, I think I will probably get the test. I've had a polyp removed in a colonoscopy so knowing if I have colon cancer related mutations might affect the frequency of me and my siblings colonoscopies. I also have persistent PSA immediately post RP, which can point to metastatic disease, but I don't worry about
at all because it shows up on only one brand of assay made by Siemens. Knowing that it's undetectable on five other brands of PSA assays is reassuring, but the Color test may reinforce this thought should it show no mutations of BRCA2 and CHK2. I don't think that given my situation, I would actually pay for something like PROLARIS, but at $249, with the benefit of looking at the risk of a few other cancers, it sounds useful.
Dx Age 55 Dec '16, PSA 4.313
MP MRI Jan '17: PR 5, Bn Scan -ve
Jan '17 MRI Fs BX 4 of 12 +ve G7 (3+4)
RALP Feb 2, 2017
Path: G7 (3+4), PT2c ECE, Margins, LN, SV all -ve
2017: 0.029-0.059(Siemens); <0.008(Abbott); <0.03(NCCS); < 0.01(Bck Coulter, NUS),<0.02(Bck Coulter, Quest); <0.006(Roche, Labcorp)
Jan 2018: <0.008 (Abbott); <0.03(NCCS)